EU regulator advises against use of Merck's anti-parasite drug for COVID-19
EU regulator advises against use of Merck's anti-parasite drug for COVID-19
March 22 (Reuters) - The European medicines regulator on Monday advised against the use of Merck & Co's anti-parasite drug, ivermectin, for the treatment or prevention of COVID-19 outside clinical trials.
The advice from the European Medicines Agency (EMA) comes more than a month after Merck warned against the use of the drug to treat COVID-19 as its analysis of available data did not support the safety and efficacy of the drug.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by
Shailesh Kuber)
((Yadarisa.Shabong@thomsonreuters.com; Twitter:
+919742735150;)
路透3月22日-歐洲藥品監管機構週一建議不要在臨牀試驗之外使用默克公司的抗寄生蟲藥物伊維菌素治療或預防新冠肺炎。一個多月前，默克公司警告不要使用該藥物治療新冠肺炎，因為其對現有數據的分析並不支持該藥物的安全性和有效性。(Yadarisa Shabong在孟加拉國報道；編輯者：Shailesh Kuber)(Yadarisa.Shabong@thomsonreurs.com；推特： +919742735150;)
譯文內容由第三人軟體翻譯。